Search - tctmd.com

Displaying 861 - 880 of 2437

Sort: Relevancy | Date

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Strokes Increasing in STEMI Patients With Cardiogenic Shock

News Conference News TCT 2019

Strokes Increasing in STEMI Patients With Cardiogenic Shock

September 25, 2019

Analysis Hints at Survival Benefit with Revascularization in Stable Patients With Myocardial Ischemia

News

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Michael O'Riordan

September 24, 2019

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

September 20, 2019

CMR May Help Evaluate Nonculprit Lesions in STEMI Patients

News Daily News

CMR May Help Evaluate Nonculprit Lesions in STEMI Patients

September 19, 2019

MI Definitions in SCOT-HEART Prompt Outcry—Then Silence—on Twitter

News Daily News

MI Definitions in SCOT-HEART Prompt Outcry—Then Silence—on Twitter

September 19, 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

September 06, 2019

News Industry News

NobleStitch™ EL Receives Approval Of IDE To Conduct A Trial For Reduction Of Recurrent Ischemic Stroke

September 05, 2019

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

News Conference News ESC 2019

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

Yael L. Maxwell

September 03, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

Lifelong Exposure to Lower LDL and BP Linked With Big Reduction in CVD Events

News Conference News ESC 2019

Lifelong Exposure to Lower LDL and BP Linked With Big Reduction in CVD Events

Michael O'Riordan

September 02, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5

News Conference News ESC 2019

Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5

September 01, 2019

CONDI-2/ERIC-PPCI Puts the Kibosh on Ischemic Conditioning in STEMI

News Conference News ESC 2019

CONDI-2/ERIC-PPCI Puts the Kibosh on Ischemic Conditioning in STEMI

Yael L. Maxwell

September 01, 2019

Supplemental Oxygen Fails Once Again in ACS Patients: NZOTACS

News Conference News ESC 2019

Supplemental Oxygen Fails Once Again in ACS Patients: NZOTACS

Michael O'Riordan

September 01, 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.